A Dermatological Questionnaire for General Practitioners with a Focus on Hidradenitis Suppurativa by Marasca, Claudio et al.
 
Open Access Maced J Med Sci electronic publication ahead of print,  
published on October 03, 2018 as https://doi.org/10.3889/oamjms.2018.358 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                          1 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 
https://doi.org/10.3889/oamjms.2018.358 
eISSN: 1857-9655 
Public Health 
 
 
  
 
A Dermatological Questionnaire for General Practitioners with a 
Focus on Hidradenitis Suppurativa 
 
 
Claudio Marasca
1*
, Maria Carmela Annunziata
1
, Sara Cacciapuoti
1
, Mariateresa Cantelli
1
, Fabrizio Martora
1
, Silvestro 
Scotti
2
, Luigi Sparano
2
, Gabriella Fabbrocini
1
 
 
1
Department of Clinical Medicine and Surgery, Section of Dermatology and Venereology, University of Naples Federico II, 
Via Pansini 5, Naples, Italy; 
2
Board of the Italian Federation of General Practitioners, Italy 
 
Citation: Marasca C, Annunziata MC, Cacciapuoti S, 
Cantelli M, Martora F, Scotti S, Sparano L, Fabbrocini G. 
A Dermatological Questionnaire for General Practitioners 
with a Focus on Hidradenitis Suppurativa. Open Access 
Maced J Med Sci. 
https://doi.org/10.3889/oamjms.2018.358 
Keywords: Hidradenitis suppurativa; General 
practitioners; Acne inversa; Survey; Questionnaire 
*Correspondence: Claudio Marasca. Department of 
Clinical Medicine and Surgery, Section of Dermatology 
and Venereology, University of Naples Federico II, Via 
Pansini 5, Naples, Italy. E-mail: 
claudio.marasca@gmail.com 
Received: 04-Apr-2018; Revised: 28-May-2018; 
Accepted: 10-Aug-2018; Online first: 03-Oct-2018 
Copyright: © 2018 Claudio Marasca, Maria Carmela 
Annunziata, Sara Cacciapuoti, Mariateresa Cantelli, 
Fabrizio Martora, Silvestro Scotti, Luigi Sparano, Gabriella 
Fabbrocini. This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
Abstract 
BACKGROUND: Hidradenitis suppurativa (HS) is a skin chronic inflammatory disease typically located in several 
areas such as perianal, inguinal and axillary regions. In 40% to 70% of cases, general practitioners (GPs) are the 
first health care professionals consulted by patients suffering from HS. The role of GPs in HS management could 
be more substantial than it has been in the past.  
AIM: We developed a questionnaire to assess the knowledge of HS by GPs and to evaluate if in their perception 
the dermatologist is the reference medical doctor for pathology above.  
METHODS: The data were processed by a univariate descriptive statistical analysis.  
RESULTS: Our study showed GPs could recognise patients affected by HS. They have proven to know the main 
features of HS. Nevertheless, the second part of the questionnaire has highlighted the considerable confusion of 
GPs about who the reference figure is.  
CONCLUSION: The data registered regarding therapy and follow up too, only show a mild preponderance of 
dermatologist compared to other professional figures, such as a surgeon, GPs and plastic surgeon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Hidradenitis suppurativa (HS) is a chronic 
inflammatory disease, commonly characterised by 
painful, deep dermal abscesses and chronic, draining 
sinus tracts. Lesions are typically located in several 
skin areas such as perianal, inguinal and axillary 
regions [1] [2]. The prevalence rate is not finally 
defined yet: it varies between 0.0003% and 4% 
depending on the study population [3] [4]. Estimates 
from insurance databases suggest a prevalence of < 
0.1% [5] [6]. 
This variation strongly suggests a signiﬁcant 
selection bias or misclassiﬁcation, and it may be 
speculated that not all patients ask any healthcare 
consultation. Also, diagnosis of HS may usually 
be delayed for years, and even when diagnosed, is 
challenging to treat [7].  
The healthcare system identifies the general 
practitioners (GPs) as the first reference figures for 
the citizen in the health care. The situation does not 
change for HS. 
In 40% to 70% of cases, GPs are the first 
health care professionals consulted by patients 
suffering from HS [8]. The role of GPs in HS 
management could be more substantial than it has 
been in the past. Moreover, GPs are still the primary 
caregivers for 15% of patients after an HS diagnosis is 
received [7]. 
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The main goal of the study is to assess the 
knowledge of HS by GPs and to evaluate if in their 
perception the dermatologist is the reference medical 
doctor for pathology above. 
 
 
Methods 
 
At the Department of Clinical Medicine and 
Surgery, Section of Dermatology of University 
Hospital Federico II of Naples, we developed a 
questionnaire (Table 1) on HS, structured as follows: 
- 6 knowledge questions about the 
pathology; 
- 5 related questions to HS diagnosis, 
therapies and follow up. 
The paper mentioned above questionnaire 
was filled by 150 GPs from Campania, Italy. 
The results were expressed as a percentage. 
Table 1: Six knowledge questions about HS (first part of the 
questionnaire) and five questions about HS diagnosis, 
therapies and follow up (second part of the questionnaire) 
QUESTIONNAIRE (first part) 
HS manifest with painful skin lesions 
HS manifest with inflammatory nodules 
HS manifests with abscesses 
HS manifests with draining fistulas 
HS manifests with scars 
HS occurs with lesions typically localised in the following regions: axillary, inter-
inframammary, inguinal, perineal, gluteus 
Options: I do not agree – I do not know – I partially agree - I fully agree 
QUESTIONNAIRE (second part) 
The diagnostic suspicion is supported by 
In the diagnosis of HS, the reference figure is 
In the HS therapy setting, the reference figure is 
In the management of drug therapy (topical/systemic), the reference figure is 
In the follow up of HS patients, the reference figure is 
Options: Dermatologist – Surgeon – General Practitioner – Plastic surgeon 
 
 
 
Results 
 
The first part of the questionnaire consists of 
6 general questions about HS. The collected 
responses showed a good knowledge of the disease 
by GPs. More than 80% (partially agree + fully agree) 
showed to know that HS manifests with painful skin 
lesions, with inflammatory nodules, abscesses and 
draining fistulas. 
A smaller percentage of respondents (75% = 
partially + fully agree) proved to be aware of the 
anatomic sites involved by the disease and that HS is 
also characterised by scarring (Figure 1). 
In the second part of the survey, according to 
GPs involved in the study, diagnostic suspicion is 
supported by a dermatologist (24%), surgeon (26%), 
GP (38%), plastic surgeon (12%). 
 
Figure 1: Results of 6 knowledge questions about HS (first part of 
the questionnaire). The collected responses showed a good 
knowledge of the disease by GPs. More than 80% showed to know 
that HS manifests with painful skin lesions, with inflammatory 
nodules, abscesses and draining fistulas even though GPs were not 
aware that HS is also characterised by scarring 
 
In the diagnosis of HS, dermatologists are 
slightly most involved (33%) compare to the surgeon 
(24%), GP (26%) and plastic surgeon (17%). 
In the HS therapy setting the reference figure 
is dermatologist (39%), surgeon (20%), GP (26%), 
plastic surgeon (15%). 
In the management of drug therapy (topical / 
systemic) the reference figures are as follow: 
dermatologist (44%), surgeon (16%), GP (24%), 
plastic surgeon (16%). 
In the follow up of the HS the reference 
figures are as follow dermatologist (30%), surgeon 
(24%), GP (31%), plastic surgeon (15%) (Figure 2). 
 
Figure 2: Results of 5 questions about HS diagnosis, therapies and 
follow up (second part of the questionnaire). This part of the 
questionnaire has highlighted the considerable confusion of GPs 
about who the reference figure is for HS 
 
 
 
Discussion 
 
The diagnosis of HS is based on the presence 
of recurrent painful or suppurating lesions more than 
twice in 6 months in the considered ‘typical’ areas of 
the body, including axilla, genital area, perineum, 
gluteal area and, in women, infra-mammary area. 
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Long delays in diagnosis are common since HS is 
frequently misdiagnosed as a simple infection [9]. 
Our study showed that GPs could recognise 
patients affected by HS. They have proven to know 
the main features of HS. However, initial or mildly 
severe clinical frameworks can easily be confused 
with other pathologies whose overall management is 
different. This data affects the problem of delayed 
diagnosis and contributes to determining worsening 
conditions [10].  
The second part of the questionnaire has 
highlighted the considerable confusion of GPs about 
who the reference figure is. 
The data registered regarding therapy and 
follow up too, only show a mild preponderance of 
dermatologist compared to other professional figures, 
such as a surgeon, GP and plastic surgeon. 
Inadequate management is more frequently 
associated with a wrong diagnosis. The consequence 
is the worsening of clinical manifestations with an 
increase of severity degree. 
It is well known that it is easier to treat mild 
forms of HS, compared to severe forms that are less 
responsive to therapies. Also, the disease progression 
has a significant impact on the quality of life of 
patients. Furthermore, the literature shows that 
inadequate management of HS patients causes 
worsening not only of skin but also of systemic clinical 
conditions [11] [12]. 
Indeed, HS has been considered a systemic 
disease because of the possible association with 
several comorbidities like endocrine disorders, such 
as diabetes and hyperinsulinemia, acromegaly and 
Cushing disease, cardio-metabolic comorbidities, 
metabolic syndrome, obesity and other conditions like 
inflammatory bowel diseases (especially Crohn 
disease), spondyloarthropathy, genetic keratin 
disorders associated with follicular occlusion and 
squamous cell carcinoma [13] [14] [15] [16] [17] [18] 
[19] [20]. Early recognition of the HS associated 
diseases and a timely therapy improve disease 
outcome and can prevent long-term complications. 
The worsening natural history of the disease, 
together with co-morbidities, makes necessary a 
multidisciplinary approach to HS. The multidisciplinary 
assessment of patients allows a complete evaluation 
of the disease and a more comprehensive treatment 
approach compared with traditional consultation.  
In a shared and multidisciplinary approach, 
the GP plays a key role, as the first physician 
interfaces with patients suffering from HS.  
The GP should be able to recognise the 
dermatologist as the reference figure in the treatment 
of HS patients, notwithstanding the contribution of the 
other medical figures indispensable for the proper 
management of a multidisciplinary pathology, such as 
HS.  
In conclusion, this study emphasises the need 
for education of GPs to make an accurate and early 
diagnosis, to initiate treatment and obtain the best 
management of HS patients. 
Future objectives include submitting the same 
web-based questionnaire to the largest number of 
general practitioners on a national scale. 
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